References
Original articles
Rheault, M. N. et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N. Eng. J. Med. https://doi.org/10.1056/NEJMoa2308550 (2023)
Rovin, B. H. et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet https://doi.org/10.1016/S0140-6736(23)02302-4 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, M. Renoprotective effects of sparsentan: clinical trial evidence in IgA nephropathy and FSGS. Nat Rev Nephrol 20, 6 (2024). https://doi.org/10.1038/s41581-023-00795-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-023-00795-w
- Springer Nature Limited